Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

3.83
-0.1700-4.25%
Volume:271.92K
Turnover:1.05M
Market Cap:471.19M
PE:-4.22
High:4.03
Open:3.97
Low:3.82
Close:4.00
52wk High:5.17
52wk Low:1.69
Shares:123.03M
Float Shares:94.52M
Volume Ratio:1.75
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9085
EPS(LYR):-1.2666
ROE:-48.14%
ROA:-19.25%
PB:1.91
PE(LYR):-3.02

Loading ...

Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Codexis (CDXS) and LENZ Therapeutics (LENZ)

TIPRANKS
·
Aug 12

Codexis Q2 Net Loss Narrows, Helped by Lower Operating Expenses

Reuters
·
Aug 12

U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,

Reuters
·
Aug 11

C4 Therapeutics Rises After Quarterly Revenue Beat

Reuters
·
Aug 11

C4 Therapeutics Q2 EPS USD -0.18 Vs. IBES Estimate USD -0.23

Reuters
·
Aug 11

C4 Therapeutics Q2 Revenue Beats Estimates, Helped by Roche Collaboration

Reuters
·
Aug 11

C4 Therapeutics Q2 FY26 Net Loss Narrows to $23.6 Million; Revenue Rises to $6.6 Million

Reuters
·
Aug 11

C4 Therapeutics Q2 EPS USD -0.18 VS. Ibes Estimate USD -0.23

THOMSON REUTERS
·
Aug 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

C4 Therapeutics Grants New Hire Stock Options for 162,880 Shares Under NASDAQ Inducement Rule

Reuters
·
Aug 11

C4 Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 11

C4 Therapeutics, Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview

Reuters
·
Aug 03

C4 Therapeutics Shareholders Back Directors, Pay and Auditors

TIPRANKS
·
Jun 25

C4 Therapeutics Shareholders Approve Amendment to 2020 Stock Incentive Plan Evergreen Provision

Reuters
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Eli Lilly & Co (LLY) and C4 Therapeutics (CCCC)

TIPRANKS
·
Jun 22

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 18

Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV)

TIPRANKS
·
Jun 12

C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D

MT Newswires Live
·
Jun 11

C4 Therapeutics presentation highlights cemsidomide development, targeted protein degrader pipeline strategy

Reuters
·
Jun 11

C4 Therapeutics says cemsidomide posts 53% response rate in Phase 1 relapsed/refractory multiple myeloma trial at 100 µg dose

Reuters
·
Jun 11